Beyond our analysis of the targeting of signaling nodes upstream of KRAS, our finding that SHOC2 is the strongest node that augments SHP2 inhibition indicates the clear importance of targeting MAPK activation downstream of RAS in these tumors, similar to the strength of SHOC2 as a target to complement MEK inhibition in KRAS-mut cancers (33). This evidence concerns the gene KRAS and cancer.